Pharmacogenetics of coumarin anticoagulant therapy
van Schie, Rianne M. F.; Verhoef, Talitha I.; de Boer, Anthonius; van der Meer, Felix J. M.; Redekop, William K.; Schalekamp, Tom; Maitland-Van der Zee, Anke-Hilse; Grech, Godfrey
(2015) Preventive and Predictive Genetics, pp. 307 - 328
Advances in Predictive, Preventive and Personalised Medicine, pp. 307 - 328
(Part of book)
Abstract
Coumarins are effective drugs for treatment and prevention of thromboembolic events. However, their use requires a balancing act between the chance of underdosing which increases the risk of thromboembolic events and the chance of overdosing which increases the risk of haemorrhages. It has been shown that polymorphisms in VKORC1 and
... read more
CYP2C9 explain 35-50% of the dose variability, although patient characteristics and environmental factors also play a role. In this book chapter we discuss the pharmacogenetics of coumarin derivatives, clinical trials investigating the effectiveness of pre-treatment genotyping and the cost-effectiveness of pharmacogenetic-guided dosing.
show less
Download/Full Text
Keywords: Adverse drug reaction, Pharmacogenetics, Predictive genotyping, Translation, abacavir, coumarin, phenprocoumon, warfarin, anticoagulant therapy, bleeding, clinical practice, clinical trial (topic), cost effectiveness analysis, drug stability, environmental factor, genetic polymorphism, genetic variability, genotype, human, pharmacogenetics, predictive value, quality adjusted life year, thrombocytopenia, venous thromboembolism, Taverne
ISSN: 2211-3495
ISBN: 978-3-319-15343-8
978-3-319-15344-5
Publisher: Kluwer Academic Publishers, UK
(Peer reviewed)
